AC Immune

AC Immune has received FDA Fast Track designation for its drug candidate Aci-7104 for the treatment of Parkinson’s disease. The designation is intended to speed development and approval; Aci-7104 is in a phase 2 study (Vacsyn) and showed safety, tolerability and an immune response in all participants. The vaccine targets misfolded alpha-synuclein proteins in the brain and is intended for use in early stages of the disease. » Más en finanzen.net

AC Immune reports 12‑month interim data from the first three cohorts of the Phase‑1b/2 ABATE study in prodromal Alzheimer’s disease. ACI‑24 was generally safe and well tolerated at the doses tested; no ARIA‑E cases occurred, and anti‑Abeta antibody responses showed a dose‑response relationship. A fourth cohort (AD4) with an additional adjuvant was initiated to boost immunogenicity. AC Immune holds an option and license agreement with Takeda and has already received upfront and milestone payments; further payments and royalties are possible. » Más en de.investing.com

AC Immune has received a $4 million research grant from the Vijay and Marie Goradia Charitable Foundation to fund a two‑year extension of part 1 of the phase 2 VacSYn study with ACI-7104 for early‑stage Parkinson’s. The funds are intended to finance long‑term safety and efficacy data; final data from part 1 are expected in the second half of 2026. The company has a market capitalization of $210 million, its stock is down about 32% year‑to‑date and trades at $2.12. » Más en de.investing.com

Phase‑1 data show that the PET tracer ACI‑19626 has increased uptake in ALS patients compared with healthy controls, particularly in the brainstem and precentral gyrus. The tracer demonstrated good safety, acceptable dosimetry, and rapid brain uptake and clearance. The Phase‑1 study has been expanded (part 2) and can include up to 30 patients with FTD, ALS, or LATE. AC Immune is valued at around USD 281 million; analysts see price targets of USD 7–12 per share. » Más en de.investing.com

AC Immune announced that co-founder and CEO Dr Andrea Pfeifer will step down at the upcoming general meeting after 23 years to spend more time with her family. Board chairman Dr Martin Züfel will serve as interim CEO while a leading industry advisor leads the search for a permanent successor. Pfeifer will move into an advisory role, become honorary chair of the board and co-chair of the scientific advisory board. The company develops precision therapeutics for Alzheimer’s and Parkinson’s and has three candidates in clinical trials, as well as partnerships with Eli Lilly, Takeda and Johnson & Johnson. » Más en de.investing.com